<i>In Silico</i> Fragment-Based Drug Design and Molecular Docking of Tranilast Analogues as Potential Inhibitors of Transforming Growth Factor- β Receptor Type 1
Transforming Growth Factor- β Receptor type 1 (TGF-βR1) is an important anticancer target involved in promoting cell proliferation, progression, and metastasis through the induction of angiogenesis and suppression of immunological responses during the late stage of malignancy. Tranilast was initiall...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Medical Sciences Forum |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-9992/14/1/75 |